MarketCap
Facebook
X
Telegram
Puma Biotechnology ROA Ratio | PBYI
Annual ROA Ratio Puma Biotechnology
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 14.38 | 14.19 | 9.37 | 0.0 | -12.85 | -24.57 | -32.18 | -43.83 | -176.38 | -109.19 | -99.77 | -87.22 | -52.37 | -49.01 | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 14.38 | -176.38 | -46.39 |
Quarterly ROA Ratio Puma Biotechnology
| 2026-Q2 | 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 9.66 | 6.93 | 18.08 | 11.52 | 6.26 | 4.75 | 7.59 | -0.55 | 2.37 | 4.62 | 4.44 | -0.1 | -20.9 | -21.62 | -23.58 | -23.4 | -17.01 | -15.32 | -21.45 | -14.6 | -11.24 | -24.57 | -23.19 | -17.5 | -34.82 | -32.18 | -39.26 | -37.55 | -38.73 | -43.83 | -70.7 | -111.84 | -141.76 | -176.38 | -166.41 | -145.81 | -125.13 | -109.19 | -106.18 | -105.34 | -105.97 | -99.77 | -103.21 | -100.04 | -96.93 | -87.22 | -73.33 | -103.67 | -132.18 | -172.38 | -171.55 | -168.19 | -164.84 | -161.48 | -165.51 | -134.97 | -104.43 | -55.41 | -18.47 | -18.47 | -18.47 |
Quarterly performance
Select metrics to display
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 18.08 | -176.38 | -63.94 |
ROA Ratio of other stocks in the Biotechnology industry
| Issuer | ROA Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Aquestive Therapeutics
AQST
|
-52.23 | $ 3.66 | -3.82 % | $ 391 M |  USA |
 |
Jaguar Health
JAGX
|
-0.14 | $ 0.4 | -19.71 % | $ 933 K | USA |
 |
Arvinas
ARVN
|
-11.28 | $ 6.56 | -11.66 % | $ 465 M | USA |
 |
Cerus Corporation
CERS
|
-7.04 | $ 2.13 | -12.01 % | $ 406 M | USA |
 |
Beam Therapeutics
BEAM
|
-5.4 | $ 25.84 | -7.03 % | $ 2.56 B | USA |
 |
Moderna
MRNA
|
-22.87 | $ 241.1 | -6.69 % | $ 93.8 B | USA |
 |
Fortress Biotech
FBIO
|
19.94 | $ 1.83 | -7.11 % | $ 51.1 M | USA |
 |
Inhibrx
INBX
|
-78.39 | $ 80.4 | -7.34 % | $ 3.79 B | USA |
 |
Entera Bio Ltd.
ENTX
|
-71.53 | $ 3.0 | -3.54 % | $ 139 M |  Israel |
 |
Flexion Therapeutics, Inc.
FLXN
|
-45.13 | - | - | $ 459 M | USA |
 |
Legend Biotech Corporation
LEGN
|
-17.12 | $ 22.52 | -1.1 % | $ 8.3 B | USA |
 |
CytomX Therapeutics
CTMX
|
-11.46 | $ 2.14 | -8.94 % | $ 295 M | USA |
 |
Krystal Biotech
KRYS
|
15.36 | $ 300.08 | -3.46 % | $ 8.69 B | USA |
 |
Kura Oncology
KURA
|
-37.74 | $ 6.93 | -9.0 % | $ 608 M | USA |
 |
Inhibikase Therapeutics
IKT
|
-26.63 | $ 1.45 | -7.67 % | $ 143 M | USA |
 |
Heron Therapeutics
HRTX
|
-7.82 | $ 0.28 | -6.8 % | $ 46.7 M | USA |
 |
Inovio Pharmaceuticals
INO
|
-114.39 | $ 1.45 | -10.8 % | $ 68 M | USA |
 |
Corvus Pharmaceuticals
CRVS
|
-21.51 | $ 9.73 | -7.95 % | $ 768 M | USA |
 |
Aytu BioScience
AYTU
|
-13.57 | $ 1.83 | -4.69 % | $ 22.5 M | USA |
 |
Heat Biologics, Inc.
HTBX
|
-20.97 | - | -5.76 % | $ 99.8 M | USA |
 |
Innoviva
INVA
|
16.58 | $ 19.23 | -9.57 % | $ 1.3 B | USA |
 |
BioCardia
BCDA
|
-241.08 | $ 0.9 | -1.43 % | $ 6 M | USA |
 |
Kindred Biosciences, Inc.
KIN
|
-22.75 | - | 0.11 % | $ 419 M | USA |
 |
Alterity Therapeutics Limited
ATHE
|
-26.39 | $ 2.28 | -6.56 % | $ 14.6 B |  Australia |
 |
Shineco, Inc.
TYHT
|
-8.38 | - | -3.90 % | $ 97.2 M |  China |
 |
Millendo Therapeutics, Inc.
MLND
|
-83.87 | - | -5.36 % | $ 20.2 M | USA |
 |
Certara
CERT
|
-0.1 | $ 12.05 | 8.61 % | $ 1.93 B | USA |
 |
Dyadic International
DYAI
|
-74.05 | $ 0.34 | -7.09 % | $ 12.3 M | USA |
 |
Intec Pharma Ltd
NTEC
|
-67.61 | - | -12.45 % | $ 17.7 M | Israel |
 |
Anika Therapeutics
ANIK
|
-5.72 | $ 19.29 | -5.44 % | $ 277 M | USA |
 |
Aprea Therapeutics
APRE
|
-79.08 | $ 0.5 | -1.96 % | $ 3.27 M | USA |
 |
Galectin Therapeutics
GALT
|
-157.87 | $ 2.98 | -14.12 % | $ 190 M | USA |
 |
Corcept Therapeutics Incorporated
CORT
|
11.91 | $ 71.75 | -9.43 % | $ 7.45 B | USA |
 |
Progenity, Inc.
PROG
|
-124.66 | - | -3.47 % | $ 164 M | USA |
 |
Genprex
GNPX
|
-159.75 | $ 2.09 | -2.34 % | $ 1.95 M | USA |
 |
Strongbridge Biopharma plc
SBBP
|
-37.22 | - | 1.52 % | $ 136 M | USA |
 |
Innate Pharma S.A.
IPHA
|
-78.41 | $ 1.4 | -1.76 % | $ 125 M |  France |
 |
Seneca Biopharma, Inc.
SNCA
|
-124.66 | - | -1.19 % | $ 28.7 M | USA |
 |
BioMarin Pharmaceutical
BMRN
|
4.59 | $ 56.14 | -1.74 % | $ 10.8 B | USA |
 |
Matinas BioPharma Holdings
MTNB
|
-143.52 | $ 1.11 | -7.0 % | $ 6.08 M | USA |
 |
Enanta Pharmaceuticals
ENTA
|
-29.17 | $ 10.06 | -5.54 % | $ 215 K | USA |
 |
Milestone Pharmaceuticals
MIST
|
-0.06 | $ 0.69 | -10.54 % | $ 73.3 M |  Canada |
 |
Kiniksa Pharmaceuticals, Ltd.
KNSA
|
7.73 | $ 88.15 | -8.29 % | $ 6.54 B | USA |
 |
Lipocine
LPCN
|
-56.63 | $ 1.52 | 5.56 % | $ 8.28 M | USA |
 |
Seres Therapeutics
MCRB
|
4.12 | $ 2.09 | -2.63 % | $ 18.5 M | USA |
 |
Madrigal Pharmaceuticals
MDGL
|
-22.89 | $ 400.26 | -0.04 % | $ 8.98 B | USA |
 |
CEL-SCI Corporation
CVM
|
-90.25 | $ 1.35 | -2.88 % | $ 10.8 M | USA |
 |
Inventiva S.A.
IVA
|
-154.84 | $ 3.65 | -5.68 % | $ 218 M | France |
 |
MeiraGTx Holdings plc
MGTX
|
-46.72 | $ 8.51 | -9.71 % | $ 684 M | USA |
 |
Eton Pharmaceuticals
ETON
|
-4.99 | $ 47.29 | -6.76 % | $ 1.27 B | USA |